Modern Management of Differentiated Thyroid Cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 689-705

  Cohen, Jason B ^a   Kalinyak, Judy E ^a   McDougall, I Ross ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Follicular cancer; Papillary cancer; Positron emission tomography; Radioiodine 123; Radioiodine 131; Thyroglobulin; Thyroid cancer

Indexed keywords

ANTIEMETIC AGENT; RADIOACTIVE IODINE; RADIOISOTOPE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

AGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; DIAGNOSTIC IMAGING; FEMALE INFERTILITY; HUMAN; LYMPH NODE METASTASIS; MALE INFERTILITY; METASTASIS; NAUSEA; OLIGOSPERMIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW; SIALOADENITIS; SUBFERTILITY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROIDITIS; TREATMENT OUTCOME; TREATMENT PLANNING; WHOLE BODY SCINTISCANNING;

EID: 0242581559     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418247     Document Type: Review

References (135)

1. McIver B, Hay ID, Giuffrida DF, et al. There is no effective treatment for anaplastic carcinoma of the thyroid: a summary of 50 year's experience at a single institute. Surgery 2001;130:1028.
2. Adams D. Blast from the past: A cautionary tale. BMJ 2002;324:121.
3. Merhy J, Driscoll HK, Leidy JW Jr, Chertow BS. Increasing incidence and characteristics of differentiated thyroid cancer in Huntington, West Virginia. Thyroid 2001;11:1063.
4. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000;50:7.
5. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297.
6. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000;10:321.
7. De La Vieja, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: Impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083.
8. Riedel C, Dohan O, De la Vieja A, et al. Journey of the iodide transporter NIS: From its molecular identification to its clinical role in cancer. Trends Biochem Sci 2001;26:490.
9. Ain KB. Management of undifferentiated thyroid cancer. Ballieres Best Pract Res Clin Endocrinol Metab 2000;14:615.
10. Ball DW, Baylin SB, De Bustros AC. Medullary thyroid carcinoma. In: Braverman LE and Utiger RD, eds. Werner and Ingbar's the Thyroid. A Fundamental and Clinical Text, 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2000:930.
11. Gagel RF, Evans DB, Lee JE. Multiple endocrine neoplasia. In: Pinchera A, ed. Endocrinology and Metabolism. New York: McGraw-Hill, 2001:755.
12. Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metabol 2002;87:105.
13. Nakhjavani MK, Gharib H, Goellner JR, Van Heerden JA. Metastasis to the thyroid gland. A report of 43 cases. Cancer 1997;79:574.
14. Figge J. Epidemiology of thyroid cancer. In: Wartofsky L, ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press, 2000:77.
15. Ries LAG, Kosary CL, Hankey BF, et al. (eds). SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
16. Feldt-Rasmussen U. Iodine and cancer. Thyroid 2001;11:483.
17. Duffy BJ, Fitzgerald PJ. Cancer of the thyroid in children: A report of 28 cases. J Clin Endocrinol Metab 1950;10:1296.
18. Simpson CL, Hempelmann LH. The association of tumors and roentgen-ray treatment of the thorax in infancy. Cancer 1957;10:42.
19. Saenger EL, Silverman FN, Sterling TD, Turner ME. Neoplasia following therapeutic irradiation for benign conditions in childhood. Radiology 1960;74:889.
20. Roudebush CP, Asteris GT, DeGroot LJ. Natural history of radiation-associated thyroid cancer. Arch Intern Med 1978;138:1631.
21. Samaan NA, Schultz PN, Ordonez NG, et al. A comparison of thyroid carcinoma in those who have and have not had head and neck irradiation in childhood. J Clin Endocrinol Metab 1987;64:219.
22. Thompson DE, Mabuchi K, Ron E, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994;137:S17.
23. Stsjazhdo VA, Tsyb AF, Tronko ND, et al. Childhood thyroid cancer since accident at Chernobyl. BMJ 1995; 310:801.
24. Ito T, Seyama T, Iwamoto KS, et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994; 344:259.
25. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Research 1995; 55:5617.
26. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690.
27. Klugvauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995;11:2459.
28. Pisarchik AV, Ermak G, Fomicheva V, et al. The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. Thyroid 1998;8:133.
29. Figge J. Molecular pathogenesis of thyroid cancer. In: Wartofsky L, ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press, 2000:57.
30. Rogue L, Nunes VM, Ribeiro C, Martins C, et al. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001;92:2529.
31. Carlisle MR, McDougall IR. Familial differentiated carcinoma of the thyroid. In: Biersack HJ, Grunwald F, eds. Thyroid Cancer in the Year 2000. Heidelberg/New York: Springer, 2001:55.
32. Hay ID. Papillary thyroid carcinoma. Endocrinol Metabol Clin N Am 1990;19:545.
33. Simpson WJ, McKinney SE, Carruthers JS, et al. Papillary and follicular thyroid cancer: Prognostic factors in 1578 patients. Am J Med 1987;83:479.
34. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001;7:637.
35. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institute during 1940 through 1989. Surgery 1993;114:1050.
36. Schlumberger M, Pacini F. Thyroid Tumors. Paris: Editions Nucleon, 1999.
37. Mazzaferri E. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421.
38. Voutilainen PE, Multanen MM, Leppaniemi AK, et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001;11:953.
39. Matsubayashi S, Kawai K, Matsumoto Y, et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration of the thyroid gland. J Clin Endocrinol Metabol 1995;80:3421.
40. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947.
41. Mazzaferri EL, Jiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular cancer. Am J Med 1994;89:418.
42. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241.
43. Van Wyngaarden KM, McDougall IR. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 1997;7:343.
44. Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: The impact of therapy on 576 patients. Medicine 1977;56:171.
45. Crile G. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer 1957;10:1119.
46. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319.
47. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999; 130:750.
48. Mikosch P, Jauk B, Gallowitsch HJ, et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: A comparison with other disorders affecting bone metabolism. Thyroid 2001;11:257.
49. Benua RS, Sonenberg M, Leeper RD, Rawson RW. An 18 year study of the use of beef thyrotropin to increase I-131 uptake in metastatic thyroid cancer. J Clin Endocrinol Metab 1964;5:796.
50. Hays MT, Solomon DH, Werner SC. The effect of purified bovine thyroid-stimulating hormone in man. II: Loss of effectiveness with prolonged administration. J Clin Endocrinol Metab 1961;21:1475.
51. Robbins J. Pharmacology of bovine and human thyrotropin: An historical perspective. Thyroid 1999; 9:451.
52. Wartofsky L. Management of patients with scan negative, thyroglobulin positive differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:4195.
53. Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983;8:123.
54. Lakshamanan M, Schaffer A, Robbins J, et al. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med 1988;13:866.
55. Dow KH, Ferrell BR, Anelo C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613.
56. Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hormone: Development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Bio/Technology 1993;11: 1014.
57. Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999;9:447.
58. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study). J Clin Endocrinol Metab 1994;78:188.
59. Paterakis T, Ebels H, Mallick UK, et al. Lack of antigenicity of recombinant human thyrotropin after multiple injections in patients with differentiated thyroid cancer. Thyroid 2000;10:623.
60. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888.
61. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metabol 1999;84:3877.
62. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000;21:521.
63. McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001;13:39.
64. Park SG, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during 131-I scanning in patients with thyroid cancer: Comparison of studies with recombinant human TSH (rhTSH) vs hypothyroidism [abstr.]. J Nucl Med 1996;37:15.
65. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metabol 2001;86:5686.
66. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12:37.
67. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 1946;132:838.
68. Waxman A, Ramanna L, Chapman D, et al. The significance of 1-131 scan dose in patients with thyroid cancer: Determination of ablation. Concise communication. J Nucl Med 1981;22:861.
69. 131I (i.e. it does not cause stunning in differentiated thyroid cancer). Nucl Med Commun 1997;18:505.
70. Park H-M, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49.
71. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma. Thyroid 1997;7:277.
72. Muratet JP, Daver A, Minier JF, et al. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39: 1546.
73. Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10:573.
74. 131I. J Nucl Med 2000;41:1198.
75. Berbano R, Naddaf S, Echemendia E, et al. Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer. Endocrine Practice 1998;4:11.
76. Mandel SJ, Shankar LK, Yamamoto A, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2000;26:6.
77. 131I-scanning: Avoidance of negative therapeutic uptake due to stunning. Clin Endocrin 2001;55:515.
78. 123I as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocrine Practice 2001;7:244.
79. 131I in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun 1996;17:199.
80. DeGroot LJ, Reilly M. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982;96:51.
81. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937.
82. 131I in patients with thyroid carcinoma. Cancer Biother Radiopharm 2002;17:101.
83. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol 1962;87:171.
84. Leeper RR. Thyroid cancer. Med Clin North Am 1985;69:1079.
85. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 1977;122:371.
86. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000;10:393.
87. Koong SS, Reynolds JC, Movius EG, Keenan AM, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912.
88. Bakheet SM, Hammami M. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 1994; 21:604.
89. Handelsman DJ, Turtle JR. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer. Clin Endocrinol 1983:118:465.
90. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1995;35:1418.
91. 131 and the pregnant patient. AJR Am J Roentgenol 2001;176:869.
92. Osmanagaoglu K, Foulon W. Concerns about risks of irradiation during pregnancy. J Nucl Med 1998;39: 2194.
93. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrtropin. Endocrine Practice 1998;4: 282.
94. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: Preliminary therapeutic experience. J Endocrinol Invest 1999;22:30.
95. Lippi F, Angelini F, Capezzone M, et al. Effectiveness of rhTSH-stimulated radioiodine therapy in metastatic differentiated thyroid cancer. International Symposium on Thyroid and Parathyroid Tumors. Pisa, Italy: March 1999.
96. Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharmaceut 2000; 15:211.
97. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, et al. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001;11:1025.
98. Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:5.
99. Nemec J, Röhling S, Zamrazil V, Pohunková D. Comparison of the distribution of dianostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979;20:92.
100. Pacini F, Lippi L, Formica M, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum-thyroglobulin levels. J Nucl Med 1987;28:1888.
101. Zeissman HA, Bahar H, Fahey FH, Dubsky V. Hepatic visualisation on iodine-131 whole-body thyroid scans. J Nucl Med 1987;28:1408.
102. McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med 1995;20:869.
103. Wu S-Y, Brown T, Milne N, et al. Iodine131 total body scan - Extrathyroidal uptake of radioiodine. Semin Nucl Med 1986;16:82.
104. Park HM, Tarver RD, Schauwecker DS, Burt R. Spurious thyroid cancer metastases: Saliva contamination artifact in high dose iodine-131 metastases survey. J Nucl Med 1996;27:634.
105. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging of metastatic thyroid carcinoma. Clin Nucl Med 1988;13:657.
106. Serafini A, Sfakianakis G, Georgiou M, Morris J. Breast cyst simulating metastases on iodine-131 imaging in thyroid carcinoma. J Nucl Med 1998;39:1910.
107. Carlisle MR, Lu C, McDougall IR. The interpretation of 131I scans in the evaluation of thyroid cancer with an emphasis on false positive findings. Nucl Med Commun 2003;24:715.
108. Spencer CA. Thyroglobulin. In: Braverman LE and Utiger RD, eds. Werner and Ingbar's The Thyroid, a Fundamental and Clinical Text, 8th ed. New York: Lippincott Williams and Wilkins, 2000:402.
109. 131I total body scans. J Nucl Med 1980;26:1186.
110. Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 1985;23:405.
111. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488.
112. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273.
113. Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metabol 2002;87:1521.
114. 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: What is being treated? Thyroid 1997;7:669.
115. Nakada K, Katoh C, Kanegae E, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998;39:807.
116. Gallowitsch HJ, Mikosch P, Kresnik E, et al. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998;39:870.
117. Yen TC, Lin HD, Lee CH, et al. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: A comparison with iodine-131 and thallium-201 whole-body scans. Eur J Nucl Med 1994;21:980.
118. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716.
119. Wilson CJ, Woodroof JM, Girod DA. First report of Hurthle cell carcinoma revealed by octreotide scanning. Ann Otol Rhinol Laryngol 1998;107:847.
120. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma; contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 1996;81:2541.
121. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910.
122. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010.
123. Altenvoerde G, Lerch H, Kuwert T, et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langlebecks Arch Surg 1998;383:160.
124. McDougall IR, Davidson J, Segall G. Positron emission tomography of the thyroid with an emphasis on thyroid cancer. Nucl Med Commun 2001;22:485.
125. 131I whole-body scan. J Nucl Med 1999;40:486.
126. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 2000;179:457.
127. 131I]-iodine whole-body scans. J Clin Endocrinol Metabol 1999;84:2291.
128. 131I post-treatment whole body scans. J Clin Endocrinol Metab 2000;85:2082.
129. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. Eur J Nucl Med 1999;26:1547.
130. Fiene U. Fluoro-18-deoxyglucose positron emission tomograpphy in differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:492.
131. Huang TS, Chieng PU, Chang CC, Yen RF. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports. J Endocrinol Invest 1998; 21:392.
132. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363.
133. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18 FDG: Effect of oral diazepam. J Nucl Med 1996;37:1127.
134. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879.
135. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institute during 1940 through 1989. Surgery 1993;114:1050.